



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Charles Arntzen et al.

Group Art Unit: To Be Assigned

Serial No.: 09/129,298

Examiner: To Be Assigned

Filed: August 5, 1998

Attorney Docket No.: 7991-023-999

For: The Use of Mixed Duplex Oligonucleotides
to Effect Localized Genetic Changes in Plants

0280
0230
RECEIVED

SEP 25 1999

GROUP

#3/AR
11/05/98

**INFORMATION DISCLOSURE STATEMENT SUBMITTED UNDER
37 C.F.R. § 1.97(b)(3)**

Honorable Assistant Commissioner for Patents
Washington, D.C.


Sir:

In accordance with the continuing duty of disclosure imposed by 37 CFR § 1.56 Applicants submit the present Information Disclosure Statement accompanied by a List of References Cited by Applicant and copies of references A-M. Applicants request that the Examiner review the references and make them of record in the captioned application.

It is believed that this Information Disclosure Statement is submitted prior to the mailing of a first Office Action. Accordingly, pursuant to 37 CFR § 1.97(b)(3), no fee is believed to be required. However, should a fee be owed, please charge the required fee to Kimeragen Deposit Account 50-0233.


Respectfully submitted,

Date Aug 19, 1998


36,156
Daniel Hansburg (Reg. No.)
Kimeragen, Inc.
300 Pheasant Run
Newtown, PA 18940
2315-504-4444

The undersigned certifies that under 37 CFR § 1.8 that on Aug 19, 1998, this paper was deposited in the U.S. Mail addressed to the Assistant Commissioner for Patents, Washington, D. C. 20231 as First Class Mail with sufficient postage.

Date Aug 19, 1998


36,156
Daniel Hansburg (Reg. No.)